Related Experiment Video

Updated: May 17, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer

Robert A Nagourney1, Jonathan B Blitzer, Robert L Shuman

  • 1Memorial Medical Center of Long Beach, Todd Cancer Institute, Long Beach, CA, USA. rnagourney@rational-t.com

Anticancer Research
|October 13, 2012
PubMed
Abstract

Insights

This study used a novel platform to test drugs on non-small cell lung cancer (NSCLC) cells. The approach showed a significant improvement in treatment response and survival for advanced NSCLC patients.

Area of Science:

  • Oncology
  • Translational Medicine
  • Cancer Biology

Background:

  • Advanced and metastatic non-small cell lung cancer (NSCLC) presents significant treatment challenges.
  • Current treatment selection for NSCLC often relies on population-level data, not individual tumor responses.

Purpose of the Study:

  • To evaluate a functional drug-screening platform using patient-derived tumor micro-spheroids.
  • To assess the impact of drug selection on treatment outcomes in advanced NSCLC.

Main Methods:

  • Primary tumor micro-spheroids were isolated from surgical specimens of NSCLC patients.
  • Drug-induced cell death was measured using morphology and staining in a functional assay.
  • Thirty-one patients with advanced, metastatic NSCLC received therapy based on the platform's drug sensitivity profile.

Main Results:

  • A high objective response rate (ORR) of 64.5% (20/31 patients) was observed, with 1 complete and 19 partial responses.
  • This represents a two-fold improvement compared to the historical control ORR of 30% (p=0.00015).
  • Median time-to-progression was 8.5 months, and median overall survival was 21.3 months.

Conclusions:

  • The functional drug-screening platform is feasible for clinical application in NSCLC.
  • This approach demonstrated favorable outcomes in objective response rate, time-to-progression, and overall survival.
  • The platform warrants further investigation for optimizing personalized cancer therapy.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...